Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-11050 in Cutaneous Lupus Erythematosus
NCT01300208Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dovramilast in cutaneous lupus erythematosus (CLE), sponsored by Amgen. Started Oct 2010; status: completed.
02
Drugs
dovramilast
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT01300208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01300208.